Skip to main content
. 2012 Dec 31;3(12):1700–1710. doi: 10.18632/oncotarget.807

Figure 4. Prognostic prediction applying GERS in ABC/GCB subgroups of DLBCL patients.

Figure 4

The prognostic value of GERS was tested in the training cohort for DLBCL patients of ABC molecular subgroup (A, n=167), GCB molecular subgroup (B, n=183), treated by CHOP regimen (C, n=181) or by R-CHOP regimen (D, n=233).